Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
NCT00566540
Terminated
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that rema... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2021
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Head and Neck Cancer
Register for Updates
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
NCT00675259
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and help kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2018
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00729612
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation given together with carboplatin works in treating patients with stage IIIB... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/06/2018
Locations: Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Lung Cancer
Register for Updates
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
NCT01219777
Completed
The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
02/07/2018
Locations: The Ohio State University Medical Center, Columbus, Ohio
Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
NCT00201734
Terminated
This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2016
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Tumors, Unknown Primary Tumors, Adenocarcinoma
Register for Updates
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
NCT00738361
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Intraocular Melanoma
Register for Updates
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
NCT01238133
Terminated
This phase I trial studies the side effects and the best dose of gamma-secretase inhibitor RO4929097 when given together with paclitaxel and carboplatin in patients with stage II or stage III triple-negative breast cancer. Gamma-secretase inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs use in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2015
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
NCT00054028
Completed
This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2015
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Register for Updates
Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00006929
Completed
Phase II trial to study the effectiveness of combining suramin, paclitaxel, and carboplatin in treating patients who have stage IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2013
Locations: Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT00030368
Completed
Phase I trial to study the effectiveness of combining bortezomib with paclitaxel in treating patients who have advanced or metastatic solid tumors. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with paclitaxel may kill more tumor cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2013
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
NCT00005065
Completed
Phase I trial to study the effectiveness of combining carboplatin and paclitaxel, radiation therapy with gadolinium texaphyrin, and surgery in treating patients who have stage IIIA non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make the tumor cells more sensitive to radiation therapy. Combining chemother... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2013
Locations: Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio
Conditions: Stage IIIA Non-small Cell Lung Cancer
Register for Updates
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
NCT00028535
Completed
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2013
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Small Cell Lung Cancer
Register for Updates